These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

204 related articles for article (PubMed ID: 21182342)

  • 1. The impact of disease stage on direct medical costs of HIV management: a review of the international literature.
    Levy A; Johnston K; Annemans L; Tramarin A; Montaner J
    Pharmacoeconomics; 2010; 28 Suppl 1():35-47. PubMed ID: 21182342
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cost effectiveness of darunavir/ritonavir 600/100 mg bid in treatment-experienced, lopinavir-naive, protease inhibitor-resistant, HIV-infected adults in Belgium, Italy, Sweden and the UK.
    Moeremans K; Hemmett L; Hjelmgren J; Allegri G; Smets E
    Pharmacoeconomics; 2010; 28 Suppl 1():147-67. PubMed ID: 21182349
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Predicting direct costs of HIV care during the first year of darunavir-based highly active antiretroviral therapy using CD4 cell counts: evidence from POWER.
    Hill AM; Gebo K; Hemmett L; Löthgren M; Allegri G; Smets E
    Pharmacoeconomics; 2010; 28 Suppl 1():169-81. PubMed ID: 21182350
    [TBL] [Abstract][Full Text] [Related]  

  • 4. US cost effectiveness of darunavir/ritonavir 600/100 mg bid in treatment-experienced, HIV-infected adults with evidence of protease inhibitor resistance included in the TITAN Trial.
    Brogan A; Mauskopf J; Talbird SE; Smets E
    Pharmacoeconomics; 2010; 28 Suppl 1():129-46. PubMed ID: 21182348
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The cost of managing HIV infection in highly treatment-experienced, HIV-infected adults in France.
    Colin X; Lafuma A; Costagliola D; Lang JM; Guillon P
    Pharmacoeconomics; 2010; 28 Suppl 1():59-68. PubMed ID: 21182344
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Modelling the budget impact of darunavir in the treatment of highly treatment-experienced, HIV-infected adults in France.
    Colin X; Lafuma A; Costagliola D; Smets E; Mauskopf J; Guillon P
    Pharmacoeconomics; 2010; 28 Suppl 1():183-97. PubMed ID: 21182351
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Early Treatment in HIV Patients: A Cost-Utility Analysis from the Italian Perspective.
    Marcellusi A; Viti R; Russo S; Andreoni M; Antinori A; Mennini FS
    Clin Drug Investig; 2016 May; 36(5):377-87. PubMed ID: 26940802
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cost effectiveness of darunavir/ritonavir 600/100 mg bid in protease inhibitor-experienced, HIV-1-infected adults in Belgium, Italy, Sweden and the UK.
    Moeremans K; Annemans L; Löthgren M; Allegri G; Wyffels V; Hemmet L; Caekelbergh K; Smets E
    Pharmacoeconomics; 2010; 28 Suppl 1():107-28. PubMed ID: 21182347
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cost-efficacy comparison among three antiretroviral regimens in HIV-1 infected, treatment-experienced patients.
    Ruof J; Dusek A; DeSpirito M; Demasi RA
    Clin Drug Investig; 2007; 27(7):469-79. PubMed ID: 17563127
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Predicting HIV care costs using CD4 counts from clinical trials.
    Hill A; Gebo K
    Am J Manag Care; 2007 Sep; 13(9):524-8. PubMed ID: 17803366
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Contemporary costs of HIV healthcare in the HAART era.
    Gebo KA; Fleishman JA; Conviser R; Hellinger J; Hellinger FJ; Josephs JS; Keiser P; Gaist P; Moore RD;
    AIDS; 2010 Nov; 24(17):2705-15. PubMed ID: 20859193
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cost effectiveness of darunavir/ritonavir in highly treatment-experienced, HIV-1-infected adults in the USA.
    Mauskopf J; Brogan A; Martin S; Smets E
    Pharmacoeconomics; 2010; 28 Suppl 1():83-105. PubMed ID: 21182346
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Measures of site resourcing predict virologic suppression, immunologic response and HIV disease progression following highly active antiretroviral therapy (HAART) in the TREAT Asia HIV Observational Database (TAHOD).
    Oyomopito R; Lee MP; Phanuphak P; Lim PL; Ditangco R; Zhou J; Sirisanthana T; Chen YM; Pujari S; Kumarasamy N; Sungkanuparph S; Lee CK; Kamarulzaman A; Oka S; Zhang FJ; Mean CV; Merati T; Tau G; Smith J; Li PC;
    HIV Med; 2010 Sep; 11(8):519-29. PubMed ID: 20345881
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Costs to achieve undetectable HIV RNA with darunavir-containing highly active antiretroviral therapy in highly pretreated patients: the POWER experience.
    Hill AM; Clotet B; Johnson M; Stoll M; Bellos N; Smets E
    Pharmacoeconomics; 2010; 28 Suppl 1():69-81. PubMed ID: 21182345
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cost-effectiveness of different strategies to monitor adults on antiretroviral treatment: a combined analysis of three mathematical models.
    Keebler D; Revill P; Braithwaite S; Phillips A; Blaser N; Borquez A; Cambiano V; Ciaranello A; Estill J; Gray R; Hill A; Keiser O; Kessler J; Menzies NA; Nucifora KA; Vizcaya LS; Walker S; Welte A; Easterbrook P; Doherty M; Hirnschall G; Hallett TB
    Lancet Glob Health; 2014 Jan; 2(1):e35-43. PubMed ID: 25104633
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cost of medical care for HIV-infected patients within a regional population from 1997 to 2006.
    Krentz HB; Gill MJ
    HIV Med; 2008 Oct; 9(9):721-30. PubMed ID: 18643856
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Economic evaluation of ART in resource-limited countries.
    Loubiere S; Meiners C; Sloan C; Freedberg KA; Yazdanpanah Y
    Curr Opin HIV AIDS; 2010 May; 5(3):225-31. PubMed ID: 20539078
    [TBL] [Abstract][Full Text] [Related]  

  • 18. CD4 cell count and viral load monitoring in patients undergoing antiretroviral therapy in Uganda: cost effectiveness study.
    Kahn JG; Marseille E; Moore D; Bunnell R; Were W; Degerman R; Tappero JW; Ekwaru P; Kaharuza F; Mermin J
    BMJ; 2011 Nov; 343():d6884. PubMed ID: 22074713
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Long-term impact of highly active antiretroviral therapy on HIV-related health care costs.
    Keiser P; Nassar N; Kvanli MB; Turner D; Smith JW; Skiest D
    J Acquir Immune Defic Syndr; 2001 May; 27(1):14-9. PubMed ID: 11404515
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cost of treatment in a US commercially insured, HIV-1-infected population.
    Solem CT; Snedecor SJ; Khachatryan A; Nedrow K; Tawadrous M; Chambers R; Haider S; Simpson K
    PLoS One; 2014; 9(5):e98152. PubMed ID: 24866200
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.